Dr. Robert G. Szewc, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 250
Licensed in Texas since 2001, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
TX license L2686 (first issued 2001; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospital San Antonio, TX
- Baptist Medical Center San Antonio, TX
- Val Verde Regional Medical Center Del Rio, TX
Medical groups
- Robert G. Szewc, M.d., P.a. (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 250
- Services billed
- 9,350
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,324 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 811 | 177 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 754 | 94 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 272 | 90 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 219 | 39 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 202 | 64 |
| Established patient office or other outpatient visit, 20-29 minutes | 180 | 87 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 145 | 99 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 139 | 48 |
| Hemodialysis procedure with physician evaluation | 116 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pentoxifylline Other prescribers in San Antonio, TX | 337 |
| Atorvastatin Calcium Other prescribers in San Antonio, TX | 247 |
| Nifedipine Er (nifedipine) Other prescribers in San Antonio, TX | 216 |
| Losartan Potassium Other prescribers in San Antonio, TX | 181 |
| Carvedilol Other prescribers in San Antonio, TX | 164 |
| Chlorthalidone Other prescribers in San Antonio, TX | 159 |
| Furosemide Other prescribers in San Antonio, TX | 137 |
| Mounjaro (tirzepatide) Other prescribers in San Antonio, TX | 133 |
| Lisinopril Other prescribers in San Antonio, TX | 115 |
| Farxiga (dapagliflozin propanediol) Other prescribers in San Antonio, TX | 100 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 53 payments worth $1,639 in total to this clinician.
| Medtronic, Inc. | $271 |
|---|---|
| Amgen Inc. | $256 |
| Bayer HealthCare Pharmaceuticals Inc. | $214 |
| Angiodynamics, Inc. | $212 |
| Novo Nordisk Inc | $131 |
| Cardiva Medical, Inc. | $127 |
| Calliditas Therapeutics US Inc. | $94.18 |
| Travere Therapeutics, Inc. | $84.16 |
| Food and Beverage | $1,639 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $165,187 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961 - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.